Anthem Biosciences IPO: Check Day 1 subscription status, GMP trend, allotment, listing dates and more

The initial public offer of Anthem Biosciences Ltd got subscribed 73 per cent on the first day of share sale on Monday.

The initial share sale received bids for 3,21,13,406 shares against 4,40,70,682 shares on offer, according to NSE data.

Non-institutional Investors category garnered 1.55 times subscription, while the quota for Retail Individual Investors (RIIs) got subscribed 58 per cent. The portion for Qualified Institutional Buyers (QIBs) received 37 per cent subscription.

The Rs 3,395-crore IPO of the Bengaluru-based firm will close on July 16. The price band has been fixed at Rs 540-570 per share.

• Qualified Institutional Buyers (QIBs) - 0.01
• Non Institutional Investors(NIIS) - 0.90
• Retail Individual Investors (RIIs) -- 0.43
• Employee Reserved-- 0.63
• Total - 0.41

Anand Rathi has given a 'Subscribe' rating to the IPO, noting the company's consistent profitability compared to its industry peers. The brokerage highlighted the firm's strategy to sustain growth by leveraging its integrated manufacturing setup and technological strengths, with a focus on complex speciality ingredients, peptides, and probiotics. In terms of valuation, based on annualised FY25 earnings, the issue is priced at a P/E of 70.6x, with a post-issue market capitalisation of Rs 3,18,673 million. Anand Rathi stated that the IPO is fairly valued and expressed confidence in the company’s ability to maintain strong revenue and profitability metrics, supporting their "Subscribe" recommendation.

• European markets mostly fell Monday while Asia was mixed as investors digested Donald Trump's latest trade war salvos that saw him threaten to hit the European Union and Mexico with 30 percent tariffs.
• The US president's outburst came after a series of announcements last week including warnings of 50 percent levies on copper and Brazilian goods, 35 percent on Canadian goods, and a possible 200 percent charge on pharmaceuticals.
• While observers warn the measures could deal a hefty blow to the global economy, investors are largely optimistic that governments will hammer out agreements before the White House's August 1 deadline.
• In announcing his latest measures on Saturday, Trump cited Mexico's role in illicit drugs flowing into the United States and a trade imbalance with the European Union. - AFP

• Expert Opinion: Arun Kejriwal, Founder of Kejriwal Research and Investment Services, advises investors to consider applying for the book-built IPO.
  Business Overview:
• The company is a Contract Research, Development and Manufacturing Organization (CRDMO).
• It has fully integrated operations across drug discovery, development, and manufacturing.
• Possesses capabilities in both New Chemical Entities (NCE) and New Biological Entities (NBE).Financials (FY ended March 2025):
• Revenue: Rs 1,844.55 crore
• Profit After Tax (PAT): Rs 451 crore
• Net Margins: 23.4%
• Earnings Per Share (EPS): Rs 8.04
• Price-to-Earnings (P/E) Ratio: 67.16–70.90 (fully diluted basis)
• Promoter Confidence:
• The promoter-founder will retain over 52% stake post-issue.
• Not selling a single share in this IPO, which is entirely an Offer for Sale (OFS).
• Kejriwal highlights this as a major positive, especially in a market where investors are increasingly cautious about full OFS issues.

Wholesale inflation dips to a 20-month low of -0.13 percent compared with 0.4 percent in the previous month

It has been a bit of a tough 2025 for Apple. It seems to be losing ground in the AI arms race by the hour. iPhone sales in China are dwindling and there seems to be quite a but of pressure on its leader-in-chief. A report by Bloomberg states that despite the pressure, there are no signs of Apple CEO Tim Cook packing it in. At 64, Apple’s long-serving CEO shows no signs of packing his bags — and the board isn’t nudging him either. As per the report, despite Apple’s AI stumbles, sluggish innovation, and the erosion of its product-focused culture, Cook remains the board’s North Star — much like Bob Iger at Disney or Jamie Dimon at JPMorgan. (Read More)

• We Have Seen Tremendous Growth In The Last Few Years
• Outlets Opening at New Airports, Noida & Navi Mumbai
• PAT Margin Has Been Stable at 20% & We Expect This To Continue
• Currently at 445 Outlets as of March-End
• We Have Maintained 20–25% PAT Growth

Travel Food Services shares made a muted debut on the stock exchanges on Monday, listing at a premium of just over 2 percent against the IPO price. Travel Food Services stock was listed at Rs 1,125 on the National Stock Exchange, up 2.27 percent from the issue price of Rs 1,100. On the BSE, it opened at Rs 1,126.20, reflecting a premium of 2.38 percent. Post listing, the company’s market capitalisation stood at Rs 14,829.74 crore. (Read More)

According to investorgain.com, the last updated GMP (Grey Market Premium) for Anthem Biosciences IPO as of July 14, 2025, 08:37 AM, is Rs 100. Based on the price band of Rs 570.00, the estimated listing price is Rs 670 (cap price + today's GMP). This suggests a potential gain of approximately 17.54% per share.

India has had a predictable policy regime under Mr. Modi’s leadership, which supports investment and deal activity, and it has emerged as the largest and the highest IRR ( internal rate of return) market in APAC for many financial sponsors, Aiyengar adds (Read More)

• Ajay Bhardwaj
• Co Is a Partner To Global Innovators, Helping Them Research & Discover New Drugs
• Revenue Flow Comes From Molecules That Are Discovered & Commercialised
• Get Paid For The Milestones Achieved & Work On A Fee-for-service Mode

The Company will not receive any portion of the proceeds from the Offer (“Offer Proceeds”). The entire Offer Proceeds, after deducting Offer-related expenses and applicable taxes, will be received by the Selling Shareholders, who will bear these costs individually.

Rupee Opens At 86/$ Vs Friday’s Close Of 85.80/$

Ola Electric has engaged with bankers to secure Rs 1,000-1,200 crore ($120-140 million) in private credit as the electric two-wheeler startup looks to refinance an existing bank loan, people aware of the developments said. This will be the Bengaluru-based company’s second fundraise in under 12 months since going public in August 2024. Earlier this year, Ola Electric received board approval to raise Rs 1,700 crore by selling non-convertible debentures (NCDs) and other eligible debt securities. (Read More)

Anthem Biosciences Ltd. recorded a 30% growth in revenue and a 23% rise in profit after tax (PAT) between the financial years ending March 31, 2024, and March 31, 2025.

India has had a predictable policy regime under Mr. Modi’s leadership, which supports investment and deal activity, and it has emerged as the largest and the highest IRR ( internal rate of return) market in APAC for many financial sponsors, Aiyengar adds (Read More)

• Incorporated in 2006, Anthem Biosciences Limited is a technology-driven, innovation-led Contract Research, Development, and Manufacturing Organization (CRDMO). The company offers end-to-end solutions across the pharmaceutical value chain—from drug discovery and development to full-scale manufacturing.
• Anthem Biosciences caters to a wide spectrum of global clients, ranging from emerging biotech startups to large multinational pharmaceutical companies.
• The company specializes in the production of fermentation-based active pharmaceutical ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
• For the six-month period ending September 30, 2024, Anthem was involved in the manufacture of APIs and intermediates for ten commercial molecules—all of which it has supported since the early stages of discovery.

China imports up 1.1% in June, above forecasts: official data

After all the bruising, the Indian banking sector seems to be catching a breath. The Reserve Bank of India’s latest Financial Stability Report is a study in cautious optimism, with the gross non-performing assets (NPA) ratio of 46 scheduled commercial banks at a multi-decadal low of 2.3 percent as of March 31, 2025. (Read More)

DMart, NCC, Kolte Patil, VIP Industries, Sula Vineyards, Wockhardt, Akzo Nobel, Gland Pharma, Travel Food Services in focus on 14 July (Read More)

Sebi had directed impounding of Rs 4843.5 crore in an interim order on July 3 and restrained the Jane Street Group from trading in markets. But if the alleged illegal gain was deposited in a separate account with lien marked in favour of Sebi, Jane Street can resume the trading. (Read More)

• Book-Running Lead Manager: JM Financial Limited
• Registrar to the Issue: KFin Technologies Limited

• Minimum Investment: Rs 14,040 (1 lot = 26 shares)
• sNII (Small Non-Institutional Investors):
• Minimum Application: 14 lots (364 shares)
• Investment Amount: Rs 2,07,480
• bNII (Big Non-Institutional Investors):
• Minimum Application: 68 lots (1,768 shares)
• Investment Amount: Rs 10,07,760

• Price Band and Lot Size
  Price Band: Rs 540 to Rs 570 per share
• Lot Size: 26 shares per lot
• Exchanges: BSE and NSE

• Subscription Opens: July 14, 2025
• Subscription Closes: July 16, 2025
• Allotment Finalization: July 17, 2025 (Thursday)
• Tentative Listing Date: July 21, 2025 (Monday)

Good morning and welcome to Moneycontrol. Today in latest business news, we are tracking top updates in IPO segment. Anthem Biosciences is launching an initial public offering (IPO) via the book-building process, with a total issue size of Rs 3,395 crore. The entire offering consists of an offer for sale (OFS) of 5.96 crore equity shares by existing shareholders—no fresh issue of shares is involved.